- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the trial is to assess the pharmacokinetics and relative bioavailability of tapentadol following administration of 3 prototype tapentadol PR granule formulations (test formulations) each containing 25 mg tapentadol, compared to 1 tablet of Palexia® PR 25 mg (reference formulation) under fasted and fed conditions. The main pharmacokinetic target parameters are Cmax and AUC0-t for tapentadol.
Inclusion criteria
- No medical condition to be investigated